AstraZeneca (AZN.L) stock price, revenue, and financials

AstraZeneca market cap is £112.6 b, and annual revenue was $24.38 b in FY 2019

£112.6 B

AZN.L Mkt cap, 29-May-2020

$6.4 B

AstraZeneca Revenue Q1, 2020
AstraZeneca Gross profit (Q1, 2020)4.9 B
AstraZeneca Gross profit margin (Q1, 2020), %77.7%
AstraZeneca Net income (Q1, 2020)750 M
AstraZeneca EBIT (Q1, 2020)1.2 B
AstraZeneca Cash, 31-Mar-20203.4 B
AstraZeneca EV127.8 B

AstraZeneca Revenue

AstraZeneca revenue was $24.38 b in FY, 2019 which is a 10.4% year over year increase from the previous period.

Embed Graph

AstraZeneca Revenue Breakdown

Embed Graph

AstraZeneca revenue breakdown by business segment: 10.7% from Other Disease Areas, 22.1% from Respiratory, Inflammation and Autoimmunity, 35.5% from Oncology, 28.3% from Cardiovascular and Metabolic Diseases and 3.4% from Other

AstraZeneca revenue breakdown by geographic segment: 17.1% from Continental Europe, 38.3% from Americas, 37.2% from Asia, Africa & Australasia and 7.5% from UK

AstraZeneca Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

Revenue

22.5b22.1b24.4b

Revenue growth, %

(2%)(2%)10%

Cost of goods sold

4.3b4.9b4.9b

Gross profit

18.1b17.2b19.5b

Gross profit Margin, %

81%78%80%

Sales and marketing expense

310.0m331.0m339.0m

R&D expense

5.8b5.9b6.1b

General and administrative expense

10.2b10.0b11.7b

Operating expense total

16.3b16.3b18.1b

EBIT

3.7b3.4b2.9b

EBIT margin, %

16%15%12%

Interest expense

664.0m741.0m772.0m

Interest income

70.0m96.0m123.0m

Pre tax profit

2.2b2.0b1.5b

Income tax expense

(641.0m)(57.0m)321.0m

Net Income

2.9b2.1b1.2b

EPS

2.41.71.0

AstraZeneca Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

3.3b4.8b5.4b

Accounts Receivable

2.8b3.0b3.6b

Inventories

3.0b2.9b3.2b

Current Assets

13.2b15.6b15.6b

PP&E

7.6b7.4b7.7b

Goodwill

11.8b11.7b11.7b

Total Assets

63.4b60.7b61.4b

Accounts Payable

3.6b1.7b1.8b

Short-term debt

2.2b1.8b2.0b

Current Liabilities

16.4b16.3b18.1b

Long-term debt

15.6b17.4b16.2b

Non-Current Liabilities

30.3b30.3b28.7b

Total Debt

17.8b19.1b18.2b

Total Liabilities

46.7b46.6b46.8b

Common Stock

317.0m317.0m328.0m

Additional Paid-in Capital

4.4b4.4b7.9b

Retained Earnings

8.2b5.7b2.8b

Total Equity

16.6b14.0b14.6b

Debt to Equity Ratio

1.1 x1.4 x1.2 x

Debt to Assets Ratio

0.3 x0.3 x0.3 x

Financial Leverage

3.8 x4.3 x4.2 x

AstraZeneca Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

2.9b2.1b1.2b

Depreciation and Amortization

3.0b3.8b3.8b

Accounts Receivable

83.0m(523.0m)(898.0m)

Inventories

(548.0m)(13.0m)(316.0m)

Accounts Payable

415.0m(103.0m)868.0m

Cash From Operating Activities

3.6b2.6b3.0b

Purchases of PP&E

(1.3b)(1.0b)(979.0m)

Cash From Investing Activities

(2.3b)963.0m(657.0m)

Short-term Borrowings

336.0m(98.0m)(516.0m)

Long-term Borrowings

(1.8b)(1.4b)(1.7b)

Dividends Paid

(3.5b)(3.5b)(3.6b)

Cash From Financing Activities

(2.9b)(2.0b)(1.8b)

Net Change in Cash

(1.7b)1.5b547.0m

Interest Paid

698.0m676.0m774.0m

Income Taxes Paid

454.0m537.0m1.1b

AstraZeneca Ratios

USDY, 2020

EV/EBIT

104.7 x

EV/CFO

919.1 x

Debt/Equity

1.5 x

Debt/Assets

0.3 x

Financial Leverage

4.7 x

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016Q1, 2017Q2, 2017Q3, 2017Q4, 2017FY, 2017Q1, 2018Q2, 2018Q3, 2018Q4, 2018FY, 2018Q1, 2019Q2, 2019Q3, 2019Q4, 2019FY, 2019Q1, 2020

Projects in R&D Pipeline

99 133 146 132 144 149 167

Phase I Trials Projects

33 24 44 41 50 38 34

Phase II Trials Projects

27 11 33 36 37 43 50

Phase III Trials Projects

19 11 35 27 23 22 27

Life-cycle Management Projects

34 46 56

Blood Pressure Screenings (Africa)

5.70 m9.97 m13.50 m

New Phase I Projects

3 5 2 8 5 3 4 3 1 1 1 5 3

New Phase II Projects

2 2 1 6 2 3 4 12 1 4 5 2

New Pivotal Study Projects

5 3 1 3 2 1 5 6 6 6 3 1

New Projects to Registration

3 1 4 1 3 1 3 1 5 5

NME Phase I (Oncology)

16 18 17 21 21 19 18 17 26 26 21 21 20 18 18 20

NME Phase II (Oncology)

8 7 6 3 3 4 10 10 20 20 25 22 25 27 27 25

NME in Late-stage Development (Oncology)

4 4 4 5 5 4 4 4 11 11 14 17 14 12 12 7

NME Phase I (Biopharmaceuticals)

16 18 17 13 13 12 12 13 13 13 13 13 14 16 16 17

NME Phase II (Biopharmaceuticals)

17 15 15 18 18 17 17 17 23 23 22 22 21 22 22 20

NME in Late-stage Development (Biopharmaceuticals)

5 5 4 4 4 4 3 2 3 3 3 3 5 5 5 4

Healthcare Workers Trained

10.82 k35.89 k81.61 k

People Reached (Healthcare Programmes)

7.17 m12.01 m16.42 m

People Reached (Patient Assistance Programmes)

9 m9.30 m9.70 m

NME Phase I

34 26 32

NME Phase II

20 25 39

NME in Late-stage Development

11 8 8

Countries

100 100 100

Health Facilities Activated

827 2 k2.62 k

Patients Included in Clinical Trials

33 k

Scientific Collaborations

600 630 730

Young Health Programme Members

2.25 m3.01 m4.01 m

AstraZeneca Human Capital

FY, 2019FY, 2018FY, 2017
Male, percent50 %49.9 %49.9 %
Female, percent50 %50.1 %50.1 %

Job Roles

FY, 2019FY, 2018FY, 2017
Male (Senior and Middle Management), percent13.7 %13.9 %13.9 %
Female (Senior and Middle Management), percent11.4 %11.2 %11.1 %
Female (Management), percent10.4 %10.4 %10.2 %
Female (Executive Leadership), percent8 %7.6 %7 %
Male (Executive Leadership), percent17 %17.5 %18 %
Female (Board), percent8.3 %10.5 %10.5 %
Male (Board), percent16.7 %14.5 %14.5 %
Male (Management), percent14.7 %14.7 %14.8 %

AstraZeneca Employee Rating

3.93038 votes
Culture & Values
3.9
Work/Life Balance
3.8
Senior Management
3.4
Salary & Benefits
4.0
Career Opportunities
3.6
Source